Ann: Opthea to Host Key Opinion Leader Event on April 3, 2024, page-42

From the clip:
“We are excited to test sozinibercept in large P3 programmes […] with the goal of […] showing that we can improve visual acuity hopefully by up to 5 letters or more.“

To my memory, this is the first time somebody sharing responsibility for running the trials dares to explicitly mention a „5 letters or more“ improvement as what OPT internally is really hoping for. If this hope materializes then Eichenbaum is absolutely right saying that sozinibercept would disrupt the wAMD market.

I just cannot believe existing players continuing to stay quiet with this disruptive opportunity being up for sale / partnership just 15 months ahead of P3 results. Therefore, I’d indeed expect a partnership occurring over the next 3 months being more probable than a classic CR.